Research Became a Lifeline: A Mother and Daughter Navigate T1D
This article was written by Loraine Brogan and her daughter Natalie Brogan, who lives with type 1 diabetes. Loraine and Natalie are both Participant Advisory Council (PAC) members, advocates, and long-time Breakthrough T1D supporters. This story details Natalie’s diagnosis, what research means to them, and their journey to the PAC. The views expressed by the […]
New Publication: A Roadmap for Disease-Modifying Therapies for T1D
Disease-modifying therapies (DMTs) are treatments that prevent, slow, or reverse type 1 diabetes (T1D) by preserving or restoring insulin-producing beta cells. While there are several DMTs in clinical trials, there is only one that has been approved. A new Breakthrough T1D publication lays out how companies developing DMTs can incorporate strategic clinical trial design to […]
It’s Open Enrollment Season. Here’s What to Consider for 2027.
Updated on 10/15/2026 Every year around this time, open enrollment begins for individuals and families to select their healthcare coverage options for the following year. This year, there are changes coming for people with Healthcare.gov/Marketplace plans as well as Medicaid changes which will be implemented on January 1, 2027. Staying informed about your plan and […]
CRC 2026: Everything You Need to Know
Breakthrough T1D’s first-ever Clinical & Research Congress (CRC 2026), focused entirely on type 1 diabetes (T1D), has come to a close! Check out all our coverage below from the exciting weekend in Philadelphia, PA, where researchers, clinicians, industry leaders, healthcare professionals (HCPs), and the T1D community united to share updates across our entire mission. Check […]
What’s Ahead at Our First Clinical & Research Congress
After months and months of preparation, it’s finally here! Breakthrough T1D’s very first Clinical & Research Congress (CRC), a groundbreaking event focused entirely on type 1 diabetes (T1D), is happening this week from October 9-11 in Philadelphia, PA. Bringing Together People United in Our Shared Goal This scientific meeting is a groundbreaking event, uniting T1D […]
Islet Cell Therapies Take the Stage at Public Workshop
Islet cell therapies for type 1 diabetes (T1D) are in the works. In clinical trials, people are coming off external insulin—and experiencing healthy blood sugar levels. Researchers and clinicians are working hard behind the scenes to advance next-generation manufactured islet cell therapies as scalable cures. The momentum is real—and it’s more important than ever to […]
Finerenone Approved for Chronic Kidney Disease Associated With T1D
Finerenone is the First Therapy Approved in 30 Years for Kidney Disease and T1D Today, the U.S. Food and Drug Administration (FDA) approved finerenone (brand name Kerendia) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). UACR is a measure of kidney damage, and reducing […]
An Interview with Breakthrough T1D-Funded Researchers
A cornerstone of Breakthrough T1D is awarding funding to scientists, researchers, and clinicians who are embarking on promising type 1 diabetes (T1D) research projects. The research we fund spans across the entire spectrum of T1D, including underlying biological and genetic causes, new approaches to cures, advanced technologies, clinical trials, and more. Here, we feature Remi […]
A Roadmap to Accelerate Cell Therapies into Clinical Trials
What’s Happening? A new Breakthrough T1D publication lays out the first clear preclinical testing and manufacturing roadmap for getting islet cell therapies for type 1 diabetes (T1D) into human clinical trials faster. What is This Publication About? Before any new therapy—including islet cell therapies for T1D—can move into in-human clinical trials, they need to go […]
Tzield Approved for Stage 3 T1D in the U.S.
What’s Happening? In an exciting update for the type 1 diabetes (T1D) community, Tzield—the first disease-modifying therapy approved by the FDA to delay progression of stage 2 T1D—has now been approved by the FDA for use in stage 3 T1D. People aged 8-17 with stage 3 T1D will soon be able to get Tzield in clinics (with a prescription) if […]
